Home > Healthcare > Pharmaceuticals > Finished Drug Form > Non-opioid Pain Patch Market

Non-opioid Pain Patch Market Trends

Report ID: GMI11974
Published Date: Oct 2024
Report Format: PDF

Download Free Sample

Non-opioid Pain Patch Market Trends

The ongoing opioid crisis has heightened the need for safer, non-addictive pain management alternatives. This has led to increased interest and investment in non-opioid pain patches, which offer effective pain relief without the risk of addiction.
Innovations in adhesive materials and controlled-release mechanisms are enhancing the efficacy and convenience of pain patches. These advancements are making non-opioid pain patches more effective and user-friendly, driving higher adoption rates among patients and healthcare providers.
The global aging population is contributing to market growth. As the prevalence of chronic pain conditions rises with age, there is an increasing demand for effective pain management solutions like non-opioid pain patches.
Growing awareness about the adverse side effects of opioid-based medications is prompting patients and healthcare providers to seek alternative treatments. This shift in preference is positively impacting the market.
The increasing incidence of sports-related injuries and musculoskeletal disorders is fueling the demand for non-opioid pain patches. Athletes and active individuals are opting for these patches to manage pain effectively without the risk of addiction.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global non-opioid pain patch industry was valued at USD 828.3 million in 2023 and is estimated to grow at a 6.6% CAGR from 2024 to 2032, driven by the increasing prevalence of chronic pain conditions.

The lidocaine segment generated USD 357 million in revenue in 2023 and is expected to grow significantly due to its effectiveness in providing localized pain relief without opioids.

U.S. non-opioid pain patch market recorded USD 244.3 million in 2023 and is projected to witness substantial growth, fueled by stringent regulations on opioid prescriptions and FDA guidelines promoting non-opioid alternatives.

Key players in the market include Acorda Therapeutics, AdhexPharma, Endo Pharmaceuticals, Glaxo SmithKline, Grünenthal, Hisamitsu Pharmaceutical, IBSA Institut Biochimique, Johnson & Johnson, Mylan (Viatris), and Nichiban.